

Rectal Cancer - Pipeline Review, H2 2016

Rectal Cancer Global Market 2016 Analysis and Forecast to 2021

PUNE, INDIA, November 11, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for <u>Rectal Cancer</u>, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,



the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.

Get Sample Report @ <u>https://www.wiseguyreports.com/sample-request/643482-rectal-cancer-pipeline-review-h2-2016</u>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer

- The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industryspecific sources

- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects

- The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Rectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics

 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the

factors that drove them from pipeline

Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 **Rectal Cancer Overview 6** Therapeutics Development 7 Pipeline Products for Rectal Cancer - Overview 7 Rectal Cancer - Therapeutics under Development by Companies 8 Rectal Cancer - Pipeline Products Glance 9 **Clinical Stage Products 9** Early Stage Products 10 Rectal Cancer - Products under Development by Companies 11 Rectal Cancer - Companies Involved in Therapeutics Development 12 AbbVie Inc 12 Advaxis, Inc. 13 Cerulean Pharma, Inc. 14 Hanwha Chemical Corporation 15 Karyopharm Therapeutics, Inc. 16 **Regeneron Pharmaceuticals Inc 17** Taiwan Liposome Company, Ltd. 18 **Rectal Cancer - Therapeutics Assessment 19** Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 axalimogene filolisbac - Drug Profile 28 Product Description 28 Mechanism Of Action 28 **R&D** Progress 28 CRLX-101 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44

ganetespib - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 HD-204 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 nimotuzumab - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 selinexor - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 TLC-388 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 **R&D** Progress 91 veliparib - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 ziv-aflibercept - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100

Access Report @ <u>https://www.wiseguyreports.com/reports/643482-rectal-cancer-pipeline-review-h2-2016</u>

Get in touch: LinkedIn: <u>www.linkedin.com/company/4828928</u> Twitter: <u>https://twitter.com/WiseGuyReports</u> Facebook: <u>https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts</u>

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.